Perjeta for neoadjuvant breast cancer treatment, FDA approved
The FDA ( Food and Drug Administration ) has granted accelerated approval to Perjeta ( Pertuzumab ) as part of a complete treatment regimen for patients with early stage breast cancer before surgery ( ...
read article